http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 18:53:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+01++Filed+by%3A+Levine+James+E./26648958.html si-local-file:///var/storage/secattach/20260615/26648958.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+01++Filed+by%3A+Levine+James+E./26648958.html Mon, 15 Jun 2026 18:53:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+01++Filed+by%3A+Levine+James+E./26648958.html si-local-file:///var/storage/secattach/20260615/26648958.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+01++Filed+by%3A+Levine+James+E./26648958.html Mon, 15 Jun 2026 18:53:00 -0400 KZIA O.00673961 http://www.streetinsider.com/New+Coverage/Lake+Street++Starts+Kazia+Therapeutics+%28KZIA%29+at+Buy/26632971.html <p>Lake Street initiates coverage on Kazia Therapeutics (NASDAQ: KZIA) with a Buy rating and a price target of $32.00.</p><p>For an analyst ratings summary and ratings history on Kazia Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=KZIA">click here</a>. For more ratings news on Kazia Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=KZIA&amp;type=analyst">click here</a>.</p><p>Shares of Kazia Therapeutics closed at $11.50 yesterday.</p> http://www.streetinsider.com/New+Coverage/Lake+Street++Starts+Kazia+Therapeutics+%28KZIA%29+at+Buy/26632971.html Thu, 11 Jun 2026 08:12:46 -0400 KZIA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Mar+18++Filed+by%3A+Davidson+Ebru/26601041.html si-local-file:///var/storage/secattach/20260603/26601041.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Mar+18++Filed+by%3A+Davidson+Ebru/26601041.html Wed, 03 Jun 2026 20:20:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Mar+18++Filed+by%3A+Davidson+Ebru/26601041.html si-local-file:///var/storage/secattach/20260603/26601041.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Mar+18++Filed+by%3A+Davidson+Ebru/26601041.html Wed, 03 Jun 2026 20:20:00 -0400 KZIA O.00673961 http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Press+Releases/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html <p><strong>Why Investors Continue Watching One of Oncology&apos;s Most Difficult Frontiers</strong></p><p>DENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=HPegD8Qsy2WIxp07mu7Or736fnmqOGqmLo3uGf5pF17kyTwQSY-tbiGrRqrWx43ErV4sErpn1JKNQ8KcBwradG0KuPgUkjwLmgZesaIdOU0=" rel="nofollow" target="_blank"><u>www.247marketnews.com</u></a>) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types.</p> <p>Yet one of oncology's greatest challenges remains largely unsolved.</p> <p>Glioblastoma.</p> <p>Despite billions of dollars invested in research and development, glioblastoma remains one of the deadliest forms of cancer, with patients often facing limited treatment options and poor long-term survival rates. The disease's aggressive nature, combined with http://www.streetinsider.com/Globe+Newswire/The+Multi-Billion-Dollar+Search+for+Better+Glioblastoma+Treatments/26596685.html Wed, 03 Jun 2026 09:28:24 -0400 BNTX KZIA NTHI http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588779.html si-local-file:///var/storage/secattach/20260602/26588779.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588779.html Tue, 02 Jun 2026 09:05:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588779.html si-local-file:///var/storage/secattach/20260602/26588779.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588779.html Tue, 02 Jun 2026 09:05:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588760.html si-local-file:///var/storage/secattach/20260602/26588760.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588760.html Tue, 02 Jun 2026 09:03:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588760.html si-local-file:///var/storage/secattach/20260602/26588760.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588760.html Tue, 02 Jun 2026 09:03:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588741.html si-local-file:///var/storage/secattach/20260602/26588741.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588741.html Tue, 02 Jun 2026 09:02:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588741.html si-local-file:///var/storage/secattach/20260602/26588741.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588741.html Tue, 02 Jun 2026 09:02:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588707.html si-local-file:///var/storage/secattach/20260602/26588707.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588707.html Tue, 02 Jun 2026 09:01:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588707.html si-local-file:///var/storage/secattach/20260602/26588707.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++KAZIA+THERAPEUTICS+LTD+++++++++++++++/26588707.html Tue, 02 Jun 2026 09:01:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+02/26588604.html si-local-file:///var/storage/secattach/20260602/26588604.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+02/26588604.html Tue, 02 Jun 2026 09:00:00 -0400 KZIA O.00673961 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+02/26588604.html si-local-file:///var/storage/secattach/20260602/26588604.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++KAZIA+THERAPEUTICS+LTD++++For%3A+Jun+02/26588604.html Tue, 02 Jun 2026 09:00:00 -0400 KZIA O.00673961 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686